HL-032: Nivolumab and Brentuximab Vedotin (BV)–Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study
Year: 2020
Type: conference-abstract
Authors: Peter D. Cole, Christine Mauz-Körholz, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Markus Puhlmann, Stephen Francis, Mariana Sacchi, Richard A. Drachtman, Paul Harker-Murray, Thierry Leblanc, Stephen Daw, Kara M. Kelly
Institutions: Rutgers, The State University of New Jersey, Rutgers Cancer Institute, Justus-Liebig-Universität Gießen, Martin Luther University Halle-Wittenberg, Centro di Riferimento Oncologico, Hôpital de la Timone, Johns Hopkins Hospital, Princess Máxima Center, Seattle Children's Hospital, Istituto Giannina Gaslini, Santobono Children's Hospital, Institut Gustave Roussy, Seagen (United States), Bristol-Myers Squibb (United States), Children's Hospital of Wisconsin, Assistance Publique – Hôpitaux de Paris, Hôpital Robert-Debré, University College Hospital, Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3111712502